
TG Therapeutics, Inc.: updates and filings
Price
$63.34
November 20, 2026Market cap $9.6B
What Ploutos Investor adds for TG Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Results of operationsForm8-K
- Jun 12, 2026Shareholder voteForm8-K
- Jun 3, 2026Other material eventsForm8-K
- May 27, 2026Other material eventsForm8-K
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 20, 2026Material agreement entered, new material financial obligationForm8-K
- Feb 27, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operationsForm8-K
- Jan 13, 2026Regulation FD disclosureForm8-K
- Nov 10, 2025Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 5, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 3, 2025Results of operationsForm8-K
- Aug 8, 2025Shares registered for employeesFormS-8
- Aug 8, 2025Shelf registration for future offeringsFormS-3ASR
- Aug 8, 2025Quarterly reportfor the period to Jun 30, 2025Form10-Q
- Aug 4, 2025Results of operationsForm8-K
- Jun 13, 2025Shareholder voteForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | 8-K | Results of operations | Document |
| Jun 12, 2026 | 8-K | Shareholder vote | Document |
| Jun 3, 2026 | 8-K | Other material events | Document |
| May 27, 2026 | 8-K | Other material events | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 20, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Feb 27, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
| Jan 13, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 10, 2025 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 5, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 3, 2025 | 8-K | Results of operations | Document |
| Aug 8, 2025 | S-8 | Shares registered for employees | Document |
| Aug 8, 2025 | S-3ASR | Shelf registration for future offerings | Document |
| Aug 8, 2025 | 10-Q | Quarterly reportfor the period to Jun 30, 2025 | Document |
| Aug 4, 2025 | 8-K | Results of operations | Document |
| Jun 13, 2025 | 8-K | Shareholder vote | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 3, 1996. Of its note and share prospectuses (424B, FWP), the newest 40 of 52.
The full analysis
What do TG Therapeutics's filings show?
The filings are where every one of TG Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.